Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tenascin-C Extra-Domain A1 (TNC-A1)
- Target
- TNC-A1
- Molecular classification
- Extracellular Matrix Glycoprotein, Fibronectin Type III Domain
01
Overview
Tenascin-C Extra-Domain A1 (TNC-A1) is an alternatively spliced fibronectin type III (FNIII) domain of the extracellular matrix glycoprotein Tenascin-C. It is upregulated in tumors and promotes cancer cell survival, proliferation, invasion, angiogenesis, immune evasion and metastasis. TNC-A1 isoforms serve as promising targets for diagnostic imaging agents or targeted therapies.
- Other names
- Tenascin-C AD1TNC A1FNIII-A1
02
Mechanism of action
Antibody-drug conjugates targeting TNC-A1; CAR-T cell therapies targeting TNC-A1; Immunotherapy targeting TNC-A1
03
Biological functions
ImmunomodulationRegulation of T cell activationPromotion of cell survivalPromotion of cell proliferationPromotion of cell invasionPromotion of angiogenesisPromotion of immune evasionPromotion of metastasisExtracellular matrix organization
04
Disease associations
CancerGlioblastomaNeuroblastomaOsteosarcomaTumor MicroenvironmentChronic Inflammation
05
Safety considerations
Potential for off-target effects in normal tissues expressing low levels of TNC-A1Immunogenicity of therapeutic antibodies targeting TNC-A1
06
Biomarkers
TNC-A1 expression in tumors
Beyond the preview
Go deeper on Tenascin-C Extra-Domain A1 (TNC-A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenascin-C Extra-Domain A1 (TNC-A1).